BioSpace News Archive

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced positive data demonstrating the impact of PAD Technology™ in WYNZORA® Cream in three posters featured at the 42nd Annual Fall Clinical Dermatology Conference® taking place October 20-23, 2022, in Las Vegas, NV.

Premier, Inc., a leading technology-driven healthcare improvement company, announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common stock issued and outstanding.

Definitive agreement to sell 90% stake in Company’s Zilentin subsidiary with option to acquire all of Altamira’s remaining inner ear development assets in Q4 2022.

BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination with Incyte’s retifanlimab in advanced breast cancer.

Aditxt, Inc. today announces that its program Adimune™ has initiated the GMP manufacturing of drug candidate ADI™-100 as a key milestone toward its goal to begin first-in-human trials during the second half of 2023.

Sermonix Pharmaceuticals Inc. today shared additional findings from its Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1) Phase 2 study during the 4th Annual Congress of the International Society of Liquid Biopsy (ISLB) in Miami.

GlycoPath’s proprietary GlycoTyper™ immunoaffinity technology was used to distinguish between Lyme disease infection states and track treatment response through a collaboration with Drexel University College of Medicine, Philadelphia, PA.

In whitepapers posted to the company’s website this week, Nabsys has provided new details into its next generation HD-Mapping™ platform.

C₂N Diagnostics , which brings Clarity Through Innovation™ with laboratory services and leading products in the brain health field, recognizes an important milestone.

The global transplantation market size is projected to surpass around USD 27.07 billion by 2027, growing at a CAGR of 9.5% during forecast period from 2022 to 2027.